Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 meta-analysis

NCT04429711 (Biber), 2020
  NCT04429711		 RCTivermectinplaceboCOVID-19some concern
-/- suggested
  • suggested 1.6-fold increase in viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias

COVID 19 hospitalized meta-analysis

Gonzalez (IVER), 2020
  NCT04391127		 RCTivermectinplaceboCOVID 19 hospitalizedsome concern
36/37 inconclusive
    Hashim A, 2020
          NCT04591600    		 RCTivermectinstandard of careCOVID 19 hospitalizedsome concern
    		70/70 inconclusive
    • inconclusive 52 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias

    COVID-19 mild to moderate meta-analysis

    Kirti, 2021
          CTRI/2020/08/027225    		 RCTivermectinplaceboCOVID-19 mild to moderatesome concern
    		57/58 inconclusive
    • inconclusive 20 % decrease in viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
    Chaccour, 2020
          NCT04390022    		 RCTivermectinplaceboCOVID 19 outpatients, COVID-19 mild to moderatelow
    		12/12 inconclusive
    • inconclusive 8 % decrease in viral clearance ,viral clearance by day 7 (PE) with a high degree of certainty due to low risk of bias
    Krolewiecki, 2020
          NCT004381884    		 RCTivermectinstandard of careCOVID-19 mild to moderatesome concern
    		30/15 inconclusive
      NCT04523831 (Mahmud), 2020
              NCT04523831      		 RCTivermectinstandard of careCOVID-19 mild to moderatesome concern
      		200/200 safety concern
      • suggested 89 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
      • suggested 93 % increase in clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
      • suggested 56 % decrease in clinical deterioration with a moderate degree of certainty due to some concern in risk of bias
      • statistically significant 17.6-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
      Shahbaznejad, 2020
              IRCT20111224008507N3      		 RCTivermectinstandard of careCOVID-19 mild to moderatesome concern
      		35/38 inconclusive

        COVID-19 severe or critically meta-analysis

        Galan, 2021
                  RBR-8h7q82        		 RCTivermectinchloroquine and derivativesCOVID-19 severe or criticallysome concern
        		53/115 suggested
        • inconclusive 6 % decrease in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
        • suggested 86 % decrease in mechanical ventilation with a moderate degree of certainty due to some concern in risk of bias
        Galan, 2021
                  RBR-8h7q82        		 RCTivermectinhydroxychloroquineCOVID-19 severe or criticallysome concern
        		53/115 suggested
        • inconclusive 6 % decrease in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
        • suggested 86 % decrease in mechanical ventilation with a moderate degree of certainty due to some concern in risk of bias

        COVID 19 outpatients meta-analysis

        Lopez-Medina, 2021
                  NCT04405843        		 RCTivermectinplaceboCOVID 19 outpatientssome concern
        		200/200 inconclusive
        • inconclusive 7 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
        IVERCORCOVID19 (Vallejos), 2020
                  NCT04529525        		 RCTivermectinplaceboCOVID 19 outpatientslow
        		250/251 inconclusive
        • inconclusive 35 % decrease in hospitalization (PE) with a high degree of certainty due to low risk of bias
        TOGETHER (ivermectine) unpublished
                  NCT04727424        		 RCTivermectinplaceboCOVID 19 outpatientssome concern
        		677/678 inconclusive
        • inconclusive 9 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
        15 studies excluded by filtering options (11 RCT / 4 OBS)

        PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
        Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

         

        - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons